ライフサイエンスコーパス: postmenstrual

1 nt differences, including death at 36 weeks' postmenstrual age (15.5% with hydrocortisone vs 23.7% wi

2 eyes, 23.1%); persistent ROP at an advanced postmenstrual age (4 eyes, 30.8%); and/or vitreous hemor

3 8-1.64]) or BPD among survivors to 36 weeks' postmenstrual age (62.9% vs 63.0%; adjusted RR, 0.99 [95

4 se once daily in premature infants >38 weeks postmenstrual age (born prematurely but chronologically

5 ed 83 awake infants (159 eyes) at 36 1 weeks postmenstrual age (defined as the time elapsed between t

6 3 awake infants (159 eyes) at 36 +/- 1 weeks postmenstrual age (defined as the time elapsed between t

7 ad the primary outcome measured at ~35 wk of postmenstrual age (interquartile range: 34-36).

8 first treated for ROP at median 36.4 weeks' postmenstrual age (IQR, 34.6-38.7).

9 irth weight infants who survived to 38 weeks postmenstrual age (n = 122) and a control group of 16 he

10 mg/kg/dose twice daily in infants <38 weeks postmenstrual age (n=8) resulted in oseltamivir carboxyl

11 (1) BPD or mortality at 36 weeks' postmenstrual age (PMA) and (2) BPD at 36 weeks' PMA.

12 five birth parameters: gestational age (GA), postmenstrual age (PMA) and chronological age (CA) at th

13 unfavorable respiratory outcomes at 40 weeks postmenstrual age (PMA) and other outcomes, such as bron

14 a cohort of infants born less than 30 weeks postmenstrual age (PMA) and participating in the Neonata

15 s (n = 659) were born at less than 29 weeks' postmenstrual age (PMA) and/or with a birth weight of le

16 The median postmenstrual age (PMA) at first ROP diagnosis was 35.3

17 <33, BPD severity grade, and adjusted median postmenstrual age (PMA) at hospital discharge.

18 from 2013 to 2023 included GA at birth, BW, postmenstrual age (PMA) at ROP diagnosis, PMA at type 1

19 The infants' mean postmenstrual age (PMA) at the time of intervention was

20 tational age at birth 28.9 +/- 4.1 weeks and postmenstrual age (PMA) at time of video 35.9 +/- 4.6 we

21 The results were stratified by postmenstrual age (PMA) at treatment as occurring before

22 The mean level of IGFBP3 at 30-35 weeks postmenstrual age (PMA) for infants with proliferative R

23 so underwent research lung MRI at <48 weeks' postmenstrual age (PMA) from 2014 to 2022.

24 nd the whole brain in a sample of full-term, postmenstrual age (PMA) matched neonates (mean 44.0 week

25 diagnosed in clinical examination at median postmenstrual age (PMA) of 36 weeks (range: 32-43 weeks)

26 nts received their IVB injection at a median postmenstrual age (PMA) of 36.4 weeks (range, 16.0-87.9)

27 chance of requiring treatment at an average postmenstrual age (PMA) of 36.6 weeks, whereas those def

28 f ROP requiring treatment was made at a mean postmenstrual age (PMA) of 37w3d (95% CI, +/- 5d; range,

29 ARTICIPANTS: Infants born less than 30 weeks postmenstrual age (PMA) were enrolled from April 2014 th

30 , defined as oxygen requirement at 36 weeks' postmenstrual age (PMA), or mortality at 36 weeks' PMA.

31 s of VPI with GMA at preterm (35 +/- 2 weeks postmenstrual age (PMA), T1) and fidgety age (12 +/- 3 w

32 ates respiratory assessments beyond 36 weeks postmenstrual age (PMA).

33 a and by use of supplemental oxygen at 36 wk postmenstrual age (PMA).

34 term-born infants scanned at 43.5-44.5 weeks postmenstrual age (PMA).

35 m, before arresting prematurely at 40 months postmenstrual age (PMA).

36 nectome-based predictive modeling to predict postmenstrual age (PMA).

37 tudy of preterm infants born before 34 weeks postmenstrual age (PMA).

38 he rate of survival without BPD at 36 weeks' postmenstrual age (PMA).

39 es by certified imagers starting at 32-weeks postmenstrual age (PMA).

40 was performed at 31-36 weeks and 37-42 weeks postmenstrual age (PMA).

41 increased risk for death or BPD at 36 weeks' postmenstrual age (risk ratio, 1.21; 95% CI, 1.10-1.32)

42 in A for decreasing the risk of BPD at 36 wk postmenstrual age (RR: 0.83; 95% CI: 0.74, 0.93; numbers

43 ncephalography (EEG)-derived 'brain-age' and postmenstrual age (the age since the last menstrual cycl

44 - death or chronic lung disease at 36 weeks' postmenstrual age - occurred in significantly fewer infa

45 an increase of AL from 14.20 to 16.58 mm at postmenstrual age 32 weeks was calculated to expand the

46 Neonates with postmenstrual age 33 to 44 weeks at risk of or with seiz

47 n tensor imaging (DTI) scans, early in life (postmenstrual age [PMA] = 32.3 weeks) and at term-equiva

48 interaction term (early-life pain exposure x postmenstrual age [PMA] at scan).

49 ung-preterm infants (imaged from 30-36 weeks postmenstrual age [PMA]); 78% of term-aged preterm infan

50 Results A total of 75 preterm infants (mean postmenstrual age [PMA]: 29.5 weeks 2.3 [standard deviat

51 ates (1 girl and 3 boys; mean age, 38 weeks' postmenstrual age [range, 34-43 weeks]) with various sta

52 monary dysplasia or death prior to 36 weeks' postmenstrual age affects approximately 45% of VLBW infa

53 2 g/d of DHA from randomization to 36 weeks' postmenstrual age and 229 mothers (255 infants) assigned

54 ging, was acquired at approximately 32 weeks postmenstrual age and again at term-equivalent age.

55 ms were performed at 32 weeks' and 36 weeks' postmenstrual age and at 1 year's corrected age in indiv

56 he primary outcome (death prior to 36 weeks' postmenstrual age and BPD at 36 weeks' postmenstrual age

57 low-risk infants were examined at 37 weeks' postmenstrual age and followed up only if ROP was presen

58 ) imaging at a mean (SD) 39.85 (0.79) weeks' postmenstrual age and monocular grating VA measurement a

59 h or bronchopulmonary dysplasia at 36 weeks' postmenstrual age and respiratory morbidity at 1 year of

60 r analysis demonstrates that body weight and postmenstrual age are relevant predictors of pharmacokin

61 uated, 72 were female (51.8%); the mean (SE) postmenstrual age at baseline was 41.5 (0.27) weeks.

62 e for 479 mothers and 556 infants (mean [SD] postmenstrual age at birth, 27.0 [1.9] weeks; 255 [45.9%

63 arlier neonatal discharge (lower quartile of postmenstrual age at discharge for gestation) as variabl

64 out of the incubator for at least 48 hours), postmenstrual age at discharge, all-cause hospital readm

65 The median postmenstrual age at first dexmedetomidine exposure was

66 andomized clinical trial, the median (range) postmenstrual age at first treatment was 36.4 (34.7-39.7

67 Mean gestational age, birth weight, postmenstrual age at initial treatment, and follow-up pe

68 lower birth weight (P value = 0.002), lower postmenstrual age at IVB injection (P value = 0.001), lo

69 Targeting lower saturations reduced the postmenstrual age at last use of oxygen therapy (adjuste

70 using regression models adjusted for infant postmenstrual age at scan and sex.

71 Adjusting for gestational age at birth, postmenstrual age at scan, maternal age, socioeconomic s

72 as not affected by gestational age at birth, postmenstrual age at scan, sex, or multiple birth in the

73 r TBSS group comparisons based on increasing postmenstrual age at scan.

74 (OR, 2.5; 95% CI, 1.3-4.7; p = 0.006), lower postmenstrual age at the time of diagnosis, and multiple

75 Median postmenstrual age at the time of FA was 65.1 and 83.9 we

76 Lower postmenstrual age at the time of the first surgery and p

77 stational age, gender, ROP treatment method, postmenstrual age at treatment, and coincident nonocular

78 upplemental oxygen administered at 36 weeks' postmenstrual age best predicts death or serious respira

79 rly PN improved weight at discharge or 36 wk postmenstrual age by 14.9 g (5.3, 24.5 g) (observational

80 lmonary dysplasia-free survival at 36 weeks' postmenstrual age compared with placebo.

81 Incidence of death before 36 weeks' postmenstrual age did not differ significantly between g

82 rom 24 hours after birth through 32 weeks of postmenstrual age did not result in a lower risk of seve

83 113 patients ranged from 23 to 40 weeks and postmenstrual age from 27 to 83 weeks.

84 port but no supplemental oxygen at 36 weeks' postmenstrual age had similar values of shift, V . a/Q .

85 reduce the risk of BPD or death at 36 weeks' postmenstrual age in extremely preterm infants.

86 emoreceptor activity between 32 and 52 weeks postmenstrual age in preterm infants, using both quantit

87 old in the outpatient setting and 32 weeks' postmenstrual age in the inpatient setting.

88 Assessments at 52 to 54 weeks postmenstrual age included General Movements Assessment,

89 clinical outcomes assessed up to 36 weeks of postmenstrual age included necrotizing enterocolitis, de

90 gen/RS at each week between 34 and 44 weeks' postmenstrual age indicated that the predictive ability

91 n changes in preterm infants with increasing postmenstrual age is not known.

92 monary dysplasia or death before 36 weeks of postmenstrual age occurred in 52.3% of the infants in th

93 The infants had a median postmenstrual age of 27.9 weeks and a median weight of 9

94 ive-pressure support or until they reached a postmenstrual age of 32 weeks 0 days.

95 iagnosed by the need for oxygen therapy at a postmenstrual age of 36 weeks, need for mechanical venti

96 ndardized oxygen-saturation monitoring, at a postmenstrual age of 36 weeks.

97 ember 2006 and August 2010 and survived to a postmenstrual age of 36 weeks.

98 ond at term-equivalent age (TEA) at a median postmenstrual age of 43.0 weeks (IQR, 41.0-46.0 weeks).

99 ortical MK and FA measurements predicted the postmenstrual age of preterm infants accurately.

100 remedication for intubation (yes or no), and postmenstrual age of the infant (<=28 or >28 weeks).

101 Postmenstrual age of the mother at the time of examinati

102 no BPD) were imaged between 39 and 47 weeks postmenstrual age on a neonatal-sized, neonatal ICU-site

103 st 3 days of enteral feeds until 36 weeks of postmenstrual age or discharge home, whichever occurred

104 st 3 days of enteral feeding until 36 weeks' postmenstrual age or discharge home, whichever occurred

105 itoring in selected infants), at 36 weeks of postmenstrual age or discharge home, whichever occurred

106 irst 3 days of enteral feeds until 36 weeks' postmenstrual age or discharge home.

107 ower hemoglobin thresholds until 36 weeks of postmenstrual age or discharge, whichever occurred first

108 EGG monitoring was performed until 40 weeks' postmenstrual age or discharge.

109 Wales and were discharged home at 34 weeks' postmenstrual age or later.

110 4 days after birth and late CUS at 36 weeks' postmenstrual age or NICU discharge.

111 All infants who were 37 weeks postmenstrual age or older and stable were eligible for

112 prematurity (ROP) screening, were 35 weeks' postmenstrual age or older at the time of first OCT imag

113 primary outcome was death before 36 weeks of postmenstrual age or survival with bronchopulmonary dysp

114 risk of death decreased with day of life and postmenstrual age such that an infant born at 24 weeks'

115 Forty-two subjects from 31 weeks postmenstrual age to 1.5 years were imaged with a portab

116 The incidence of death before 36 weeks' postmenstrual age was 4.1% (10/241) of infants in the ex

117 ut bronchopulmonary dysplasia at 36 weeks of postmenstrual age was 43.9 percent in the group receivin

118 1 weeks' gestational age, discharge at lower postmenstrual age was also associated with increased ris

119 of an enteral DHA emulsion until 36 weeks of postmenstrual age was associated with modestly higher FS

120 y of premature infants starting at 32 weeks' postmenstrual age was conducted.

121 t incidence of BPD in survivors to 36 weeks' postmenstrual age was lower in the MIST group (81/217 [3

122 re bronchopulmonary dysplasia at 36 weeks of postmenstrual age was not significantly lower among infa

123 adian Oxygen Trial who survived to 36 weeks' postmenstrual age was performed.

124 Data at 36 weeks' postmenstrual age were analyzed via this visualization d

125 Healthy infants born between 37 and 42 weeks postmenstrual age were imaged with hand-held spectral-do

126 cular hemorrhage, and death before 40 weeks' postmenstrual age were not different between groups.

127 o 33 weeks' gestation who at 33 to 35 weeks' postmenstrual age were receiving caffeine treatment with

128 pulmonary dysplasia/death rates at 36 weeks' postmenstrual age were similar (27.1% vs 35.6%; P = .32)

129 robehavioral examinations at term equivalent postmenstrual age were used to assess cerebral structure

130 we recruited infants of less than 60 weeks' postmenstrual age who were born at more than 26 weeks' g

131 infants, the rate of survival to 36 weeks of postmenstrual age without bronchopulmonary dysplasia did

132 ased solely on oxygen dependence at 36 weeks postmenstrual age without objective measurements of stru

133 eeks' postmenstrual age and BPD at 36 weeks' postmenstrual age) also were considered separately.

134 (supplemental oxygen dependency at 36 weeks' postmenstrual age), and 86 included preterm-born partici

135 percentile on the Fenton chart at 40 weeks' postmenstrual age).

136 9 [50.2%] White; 376 [55.7%] male; mean [SD] postmenstrual age, 27.0 [1.9] weeks).

137 time points: the first in early life (median postmenstrual age, 32.9 weeks [IQR, 32.0-35.0 weeks]) an

138 first study-related eye examination (median postmenstrual age, 33 weeks; range, 29-40 weeks) who und

139 By 36 weeks' postmenstrual age, 59 of the 405 infants (15 percent) in

140 At 36 weeks' postmenstrual age, 83.2% of infants were alive in the bu

141 ssessment of preterm infants until 64 weeks' postmenstrual age, after which the WHO Child Growth Stan

142 WT, postmenstrual age, and NAT2 genotype significantly influ

143 300 eyes); 143 infants survived to 54 weeks' postmenstrual age, and the 7 infants who died were not i

144 gh risk for cerebral palsy at 52 to 54 weeks postmenstrual age, and the absence of high risk for CP m

145 re bronchopulmonary dysplasia at 36 weeks of postmenstrual age, and the primary safety outcome was su

146 need for supplemental oxygen at 36 weeks of postmenstrual age, as compared with 47 percent of those

147 , we recruited infants younger than 60 weeks postmenstrual age, born at greater than 26 weeks' gestat

148 s in any of the cardiac indices at 32 weeks' postmenstrual age, but with each week of exposure, right

149 in the Netherlands and Belgium at 36 weeks' postmenstrual age, examines the prespecified composite o

150 mong the infants who survived to 36 weeks of postmenstrual age, moderate or severe bronchopulmonary d

151 ome was a composite of death after 36 weeks' postmenstrual age, motor impairment, cognitive or langua

152 ly preterm infants who survived to 36 weeks' postmenstrual age, prolonged hypoxemic episodes during t

153 ment with the following support at 36 weeks' postmenstrual age, regardless of prior or current oxygen

154 espiratory support administered at 36 weeks' postmenstrual age, regardless of supplemental oxygen use

155 ed bronchopulmonary dysplasia at 36 weeks of postmenstrual age, the need for systemic glucocorticoid

156 til discharge from the hospital or 40 weeks' postmenstrual age, whichever was earlier; the prespecifi

157 plasia-free survival in infants at 36 weeks' postmenstrual age.

158 velopmental impairment at 22 to 26 months of postmenstrual age.

159 reterm infants aged between 30 and 55 weeks' postmenstrual age.

160 ut bronchopulmonary dysplasia at 36 weeks of postmenstrual age.

161 or bronchopulmonary dysplasia at 36 weeks of postmenstrual age.

162 y in 18 infants aged between 25 and 45 weeks postmenstrual age.

163 and 39 wk ("long-term ventilated") corrected postmenstrual age.

164 requiring supplemental oxygen at 36 weeks of postmenstrual age.

165 was defined as oxygen dependence at 36 weeks postmenstrual age.

166 s death or chronic lung disease at 36 weeks' postmenstrual age.

167 ler head circumference (P=0.04) at 36 weeks' postmenstrual age.

168 percent in the placebo group at 36 weeks of postmenstrual age.

169 eous injection through 32 completed weeks of postmenstrual age.

170 d chronic lung disease or death at 36 weeks' postmenstrual age.

171 h or bronchopulmonary dysplasia at 36 weeks' postmenstrual age.

172 s from the first examination after 30 weeks' postmenstrual age.

173 dictive value at 98% specificity at 30 weeks postmenstrual age.

174 rwent a fMRI scan between 40 and 46 weeks of postmenstrual age.

175 ce of ROP, gestational age, birth weight, or postmenstrual age.

176 -derived fortifier (control) until 34 weeks' postmenstrual age.

177 hopulmonary dysplasia, or death at 36 weeks' postmenstrual age.

178 edict bronchopulmonary dysplasia at 36 weeks postmenstrual age.

179 ts born at <1500 g after they reach 34-35 wk postmenstrual age.

180 d when the infants were older than 55 weeks' postmenstrual age.

181 er, suggesting the importance of an infant's postmenstrual age.

182 n at 28 days' postnatal age and at 36 weeks' postmenstrual age.

183 on within 3 days after birth until 40 weeks' postmenstrual age.

184 or darbepoetin (10 mug/kg) through 35 weeks' postmenstrual age.

185 4 weeks and 1 day to 39 weeks and 3 days) of postmenstrual age.

186 to four time points between 32 and 52 weeks postmenstrual age.

187 rom within 24 hours of birth until 36 weeks' postmenstrual age.

188 ge at each time point from the corresponding postmenstrual age.

189 Physiological BPD was assessed at 36 weeks' postmenstrual age.

190 matic pulse oximetry assessment at 36 weeks' postmenstrual age.

191 r 5-7 consecutive days during 29-32 weeks of postmenstrual age.

192 hopulmonary dysplasia, or death at 36 weeks' postmenstrual age.

193 charge, including death and BPD at 36 weeks' postmenstrual age.

194 pulmonary dysplasia evaluated at 36 weeks of postmenstrual age.

195 me was physiologic BPD or death by 36 weeks' postmenstrual age.

196 utcome was survival free of BPD at 36 weeks' postmenstrual age.

197 metabolite clearances was 1.0 and 0.97 years postmenstrual age.

198 h or physiological BPD assessed at 36 weeks' postmenstrual age.

199 or invasive mechanical ventilation at 36 wk postmenstrual age.

200 00 mg/m(2) from 14 days of life and 42 weeks postmenstrual age.

201 mposite outcome of death or BPD at 36 weeks' postmenstrual age.

202 posite of death or BPD assessed at 36 weeks' postmenstrual age.

203 eeds from 2-4 d of postnatal age until 40 wk postmenstrual age.

204 ortality and moderate/severe BPD at 36 weeks postmenstrual age.

205 l imaging in both eyes starting at 32 weeks' postmenstrual age.

206 (soy) emulsion without DHA until 36 weeks of postmenstrual age.

207 olitis, or late-onset sepsis) by 36 weeks of postmenstrual age.

208 d with risk for BPD or death before 36 weeks postmenstrual age.

209 s death, moderate, or severe BPD at 36 weeks postmenstrual age.

210 rowth Standards for term babies by 64 weeks' postmenstrual age.

211 combined risk for death or BPD at 36 weeks' postmenstrual age.

212 f which 1534 infants died prior to 36 weeks' postmenstrual age.

213 tinuous supplemental oxygen use at 36 weeks' postmenstrual age.

214 re pooled from study sites and stratified by postmenstrual age.

215 coherence tomography imaging at 37-42 weeks postmenstrual age.

216 rimary outcome was death or BPD at 36 weeks' postmenstrual age.

217 ith abnormalities evident by term-equivalent postmenstrual age.

218 4 hours after birth until at least 36 weeks' postmenstrual age.

219 ll infants were evaluated at term-equivalent postmenstrual age.

220 eyes requiring retreatment before 54 weeks' postmenstrual age.

221 sible in preterm infants from 32 to 47 weeks postmenstrual age: Intraretinal neovascularization did n

222 eeks' gestation underwent two MRIs at median postmenstrual ages 32 and 40 weeks that included structu

223 Study participants were monitored until postmenstrual ages of 36 to 40 weeks with pulse oximeter

224 equirement alone as the criterion at various postmenstrual ages were less predictive compared with th

225 ent response to hyperoxic testing at earlier postmenstrual ages, suggesting high peripheral chemorece

226 neic responses were more frequent at earlier postmenstrual ages.

227 to ventilatory drive was greater at earlier postmenstrual ages.

228 ria based on respiratory status at different postmenstrual ages.

229 ined stable over the 10-year period, whereas postmenstrual and postnatal age at treatment increased m

230 also blocked reepithelialization in both the postmenstrual endometrium and the mouse uterus after dec

231 variety of organisms differed from pre- and postmenstrual observations whether subjects were using t

232 ntial for endometrial neoangiogenesis during postmenstrual/postpartum repair.

233 the relevance of VEGF family members during postmenstrual repair, we have evaluated ligands, recepto

234 Defined primary symptoms were postmenstrual spotting, pain during uterine bleeding, te

235 A history of depression, postmenstrual symptom levels, and other diagnostic varia

236 trual syndrome and determined the effects of postmenstrual symptom severity and depression history as

237 The design was stratified for severity of postmenstrual symptoms and history of major depression.

238 Subjects with higher postmenstrual symptoms before treatment remained more sy

239 Higher levels of postmenstrual symptoms limit treatment response and are

240 olony counts at premenstrual versus mid- and postmenstrual visits for most microorganisms.

241 onates were collected at day 14, day 28, and postmenstrual week 36.

242 mood symptoms in the premenstrual versus the postmenstrual week); 5 of these depressed women and none

243 Eye size increased rapidly between 30 and 55 postmenstrual weeks and was comparable to that of term-b

244 investigating connectome development from 20 postmenstrual weeks to 5 years of age.

245 or imaging of 89 preterm neonates aged 31-42 postmenstrual weeks.

246 rush events in 10 preterm infants aged 32-36 postmenstrual weeks.